Legal & General Group
ELDN icon

Legal & General Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Legal & General Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6K Hold
7,000
– – ﹤0.01% 2985
2026
Q1 		$21.6K Buy
7,000
+1,667
+31% +$3.93K ﹤0.01% 2941
2025
Q4 		$8.05K Hold
5,333
– – ﹤0.01% 3288
2025
Q3 		$13.8K Hold
5,333
– – ﹤0.01% 3195
2025
Q2 		$14.5K Buy
+5,333
New +$16K ﹤0.01% 3141

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Legal & General Group's ELDN Position: Q2 2026 in Review

Legal & General Group held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 7,000 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Legal & General Group first reported a position in ELDN in Q2 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Legal & General Group held 7,000 shares of Eledon Pharmaceuticals worth $27.6K as of Q2 2026.
  • Legal & General Group left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2985 holding.
  • Legal & General Group first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.